Finance, Grants, Deals

Qiagen NV, a Dutch provider of sample and assay technologies, has acquired DxS Ltd, of Britain in a transaction that will expand Qiagen’s market position in molecular diagnostics for personalised medicine.

The European Commission’s research partnership with industry aimed at finding new ways of making drug development more efficient is preparing to launch a new series of projects valued at €156.3 million

Location

Cell Medica Ltd, an early-stage cellular therapeutics company, has received £1.95 million in new funding in order to commercialise its lead product, a cell therapy technique which protects patients from infection following a bone marrow transplant.

Location

The Wellcome Trust and Merck & Co have created a social business to develop affordable vaccines for diseases prevalent in low-income countries.

Location

A venture capital-backed antibody company called Argen-x BV has raised €9.5 million in a Series A financing round from a syndicate of investors, co-led by Forbion Capital Partners and Life Sciences Partners, both of the Netherlands.

Location

Arpida Ltd and Evolva SA have announced plans to merge to create a larger, publicly-listed biotechnology company with a pipeline of drug candidates as well as revenue-generating discovery partnerships.

Location

ProFibrix BV of the Netherlands has raised €8 million in a Series B round enabling it to carry forward plans to seek FDA authorisation for a combined Phase 2/3 trial in the US of its candidate tissue sealant for use in surgery or trauma injury, Fibrocaps.

Location

An investor in Celsis International Plc is on the verge of success in acquiring the drug toxicity detection company whose shares are listed on the London Stock Exchange. The investor is North Atlantic Value LLP (NAVLLP), part of the JO Hambro Capital Management Group.

Location

Algeta ASA is to receive $61 million upfront from Bayer Schering Pharma AG in a deal worth up to $800 million to develop and commercialise a radiopharmaceutical for bone metastases in patients with hormone-refractory prostate cancer.

Location

The Norwegian government has awarded Clavis Pharma ASA up to $1.1 million to accelerate its early clinical-stage treatment for pancreatic cancer, intravenous CP-4126. The grant was made by Innovation Norway, a state-owned company.

Location